PubMed:35096188 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/35096188","sourcedb":"PubMed","sourceid":"35096188","source_url":"https://www.ncbi.nlm.nih.gov/pubmed/35096188","text":"Oral Administration of Cryptotanshinone-Encapsulated Nanoparticles for the Amelioration of Ulcerative Colitis.\nBACKGROUND: Inappropriate macrophages phenotype transition contributes to the development of ulcerative colitis, and the poly (ethylene glycol)-block-poly (d, l-lactic acid) (PEG-PLA) nanoparticles delivery system can be utilized to improve the cryptotanshinone (CTS)-based therapy.\nMETHODS: We used a single emulsification method to prepare CTS-encapsulated nanoparticles (NPCTS). The therapeutic efficacy of NPCTS was evaluated in dextran sulfate sodium (DSS)-induced colitis mice. Then the proportion of total macrophages and M2-like macrophages were assayed with flow cytometry, and the relative content of pro-inflammatory cytokines in the colon was detected with Western blot. Bone-marrow-derived macrophages (BMDMs) were induced into M1-like macrophages, which were further incubated with NPCTS to repolarize into M2 subtype.\nRESULTS: Cryptotanshinone could induce the transition of M1 subtype to M2 subtype as indicated by up-regulated expression of arginase 1 (ARG1), interleukin (IL)-10, and CD206. In vivo, orally administrated NPCTS accumulated in the colon-infiltrated macrophages in colitis mice. It further revealed that NPCTS significantly alleviated colitis symptoms as indicated by increased body weight and colon length, decreased tumor necrosis factor (TNF)-α, IL-1β, and IL-6 content in the colon, and diminished total macrophage proportion (CD45+CD11b+F4/80+) and up-regulated M2 proportion (CD45+CD11b+F4/80+CD206hi).\nCONCLUSION: Oral administration of NPCTS could ameliorate ulcerative colitis with the conversion of M1-like macrophages to M2-like macrophages.","tracks":[{"project":"UCDIT_TEST","denotations":[{"id":"T1","span":{"begin":232,"end":236},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":261,"end":265},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":290,"end":293},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":1069,"end":1079},"obj":"GeneOrGeneProduct"},{"id":"T5","span":{"begin":1081,"end":1085},"obj":"GeneOrGeneProduct"},{"id":"T6","span":{"begin":1113,"end":1118},"obj":"GeneOrGeneProduct"},{"id":"T7","span":{"begin":1361,"end":1382},"obj":"GeneOrGeneProduct"},{"id":"T8","span":{"begin":1384,"end":1387},"obj":"GeneOrGeneProduct"},{"id":"T9","span":{"begin":1392,"end":1396},"obj":"GeneOrGeneProduct"},{"id":"T10","span":{"begin":1403,"end":1407},"obj":"GeneOrGeneProduct"},{"id":"T11","span":{"begin":1474,"end":1478},"obj":"GeneOrGeneProduct"},{"id":"T12","span":{"begin":1479,"end":1484},"obj":"GeneOrGeneProduct"},{"id":"T13","span":{"begin":1485,"end":1490},"obj":"GeneOrGeneProduct"},{"id":"T14","span":{"begin":1525,"end":1529},"obj":"GeneOrGeneProduct"},{"id":"T15","span":{"begin":1530,"end":1535},"obj":"GeneOrGeneProduct"},{"id":"T16","span":{"begin":1536,"end":1541},"obj":"GeneOrGeneProduct"}],"attributes":[{"subj":"T1","pred":"source","obj":"UCDIT_TEST"},{"subj":"T2","pred":"source","obj":"UCDIT_TEST"},{"subj":"T3","pred":"source","obj":"UCDIT_TEST"},{"subj":"T4","pred":"source","obj":"UCDIT_TEST"},{"subj":"T5","pred":"source","obj":"UCDIT_TEST"},{"subj":"T6","pred":"source","obj":"UCDIT_TEST"},{"subj":"T7","pred":"source","obj":"UCDIT_TEST"},{"subj":"T8","pred":"source","obj":"UCDIT_TEST"},{"subj":"T9","pred":"source","obj":"UCDIT_TEST"},{"subj":"T10","pred":"source","obj":"UCDIT_TEST"},{"subj":"T11","pred":"source","obj":"UCDIT_TEST"},{"subj":"T12","pred":"source","obj":"UCDIT_TEST"},{"subj":"T13","pred":"source","obj":"UCDIT_TEST"},{"subj":"T14","pred":"source","obj":"UCDIT_TEST"},{"subj":"T15","pred":"source","obj":"UCDIT_TEST"},{"subj":"T16","pred":"source","obj":"UCDIT_TEST"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"UCDIT_TEST","color":"#93e7ec","default":true}]}]}}